Ensysce Q3 net loss $3.7M; Phase 3 PF614 trial started; FDA backs PF614-MPAR

Ensysce Biosciences, Inc.

2025-Q3 EPS reported -$3.42 revenue$3,184,314

Net loss attributable to common stockholders was $3.7M for Q3 2025, vs. a gain of $0.7M in Q3 2024.
Cash totaled $1.7M as of Sept 30, 2025; completed convertible preferred stock offering in Nov 2025 for $4M gross, with up to $16M additional over 24 months.
Initiated pivotal Phase 3 trial (PF614-301) for PF614 in moderate to severe post-surgical pain in July 2025.
FDA supported PF614-MPAR development for overdose protection labeling and confirmed potential streamlined 505(b)(2) pathway.
R&D expenses increased to $3.0M from $1.7M YoY; grant revenue fell to $0.5M from $3.4M.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-25-023492
form_type: 8-K
ticker: ENSC
cik: 0001716947
company_name: Ensysce Biosciences, Inc.
filed_at: 2025-11-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.242778+00:00
generated_at: 2026-05-16T19:53:02.934155+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-25-023492
json_url: https://secwatch.observer/filing/0001493152-25-023492.json
markdown_url: https://secwatch.observer/filing/0001493152-25-023492.md
text_url: https://secwatch.observer/filing/0001493152-25-023492.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315225023492/0001493152-25-023492-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315225023492/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-25-023492

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.